Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists

Thrombosis Research

Volumn 135, Issue 5, 2015, Pages 958-962

  Honda, Yuko ^a   Morishima, Yoshiyuki ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

ADP; Edoxaban; Factor Xa inhibitor; P2Y12 receptor antagonist; Thrombin generation; Tissue factor

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; EDOXABAN; THROMBIN; THROMBOPLASTIN; TICAGRELOR; ADENOSINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; ANALOGS AND DERIVATIVES; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; METABOLISM;

ADENOSINE; ADENOSINE DIPHOSPHATE; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FACTOR XA INHIBITORS; HUMANS; PLATELET-RICH PLASMA; PURINERGIC P2Y RECEPTOR ANTAGONISTS; PYRIDINES; THIAZOLES; THROMBIN; THROMBOPLASTIN;

EID: 84928591914     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.03.001     Document Type: Article

References (19)

1. B.A. Steinberg, and J.P. Piccini Anticoagulation in atrial fibrillation BMJ 348 2014 g2116 10.1136/bmj.g2116
2. S. Kralev, K. Schneider, S. Lang, T. Suselbeck, and M. Borggrefe Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography PLoS One 6 2011 e24964 10.1371/journal.pone.0024964
3. Task Force Members, G.Y. Lip, S. Windecker, K. Huber, P. Kirchhof, and F. Marin Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur Heart J 35 2014 3155 3179 10.1093/eurheartj/ehu298
4. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151 10.1056/NEJMoa0905561
5. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891 10.1056/NEJMoa1009638
6. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 Sep 15 981 992 10.1056/NEJMoa1107039
7. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, and J.L. Halperin Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104 10.1056/NEJMoa1310907
8. W.J. Dewilde, T. Oirbans, F.W. Verheugt, J.C. Kelder, B.J. De Smet, and J.P. Herrman Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115 10.1016/S0140-6736(12)62177-1
9. D. Fitchett, A. Verma, J. Eikelboom, M. Madan, E. Cohen, and A. Bell Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation: the clinical dilemma of triple therapy Curr Opin Cardiol 29 1 2014 Jan 1 9 10.1097/HCO.0000000000000024
10. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19 10.1056/NEJMoa1112277
11. J.H. Alexander, R.D. Lopes, S. James, R. Kilaru, Y. He, and P. Mohan Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 8 2011 Aug 25 699 708 10.1056/NEJMoa1105819
12. J. Oldgren, A. Budaj, C.B. Granger, Y. Khder, J. Roberts, and A. Siegbahn Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 22 2011 Nov 2781 2789 10.1093/eurheartj/ehr113
13. D. Mezzano, T. Quiroga, and J. Pereira The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays Semin Thromb Hemost 35 2009 242 254 10.1055/s-0029-1220785
14. E.J. Favaloro, G. Lippi, and J. Koutts Laboratory testing of anticoagulants: the present and the future Pathology 43 2011 682 692 10.1097/PAT.0b013e32834bf5f4
15. R. Altman, A.S. Scazziota, L. Herrera Mde, and C. Gonzalez Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis Thromb J 4 2006 5
16. 12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk Thromb Haemost 93 2005 1128 1136
17. T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-Matsumoto, N. Sugiyama, and T. Nagahara DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles J Thromb Haemost 6 2008 1542 1549 10.1111/j.1538-7836.2008.03064.x
18. S.P. Jackson Arterial thrombosis-insidious, unpredictable and deadly Nat Med 17 2011 1423 1436 10.1038/nm.2515
19. Y. Morishima, Y. Honda, C. Kamisato, A. Kita, N. Edo, and T. Kumada Combination of edoxaban, an orally active factor Xa inhibitor with aspirin and clopidogrel in a rat model of arterial thrombosis J Thromb Haemost 9 Supplement s2 2011 901